April 2024

Progress in the Development of Targeted Anti-Tumor Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) are conjugated products of monoclonal antibodies (mAbs) and cytotoxic small molecules. In tumor treatment, although monoclonal antibodies have good targeting properties, most of them target extracellular or cell surface antigens, have weak anti-tumor activity, have limited therapeutic

Progress in the Development of Targeted Anti-Tumor Antibody-Drug Conjugates Continue Reading »